Pharmacists in Prairie Du Sac, WI Accepting Medicare
5 Pharmacists found. Showing 1 - 5
 Dr. Stephanie Lynn Purcell, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 405 Water St, Prairie Du Sac, WI 53578 Phone: 608-643-3396 Fax: 608-643-4361 |
Dr. Yuen Sim Lai, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 80 1st St, Prairie Du Sac, WI 53578 Phone: 608-643-7243 |
 Mr. Dennis John Ballweg, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1200 Prairie St, Prairie Du Sac, WI 53578 Phone: 608-643-6500 Fax: 608-643-6533 |
Caleb J Ballweg, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1200 Prairie St, Prairie Du Sac, WI 53578 Phone: 608-643-6500 |
Mr. Michael A Eannelli Sr., RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 405 Water St, Prairie Du Sac, WI 53578 Phone: 608-643-3396 Fax: 608-643-4361 |
News Archive
New rules require insurers to justify rate increases over 10%
Federal rules mandate that companies explain the hikes and submit them to regulators. Also, HHS announced that association health plans must meet the same rate scrutiny as other types of insurance.
Discovery reveals possibility of using water for finer analysis of the brain's functioning
To observe the brain in action, scientists and physicians use imaging techniques, among which functional magnetic resonance imaging (fMRI) is the best known. These techniques are not based on direct observations of electric impulses from activated neurons, but on one of their consequences. Indeed, this stimulation triggers physiological modifications in the activated cerebral region, changes that become visible by imaging.
Nanoliposomes engineered to deliver therapeutic drugs that kill malignant cells
A new way to deliver cancer-fighting drugs using tiny particles made from lipids and chemotherapy drugs may have the power to knock out malignancies with a one-two punch. The strategy holds promise for patients with many different kinds of cancers.
Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011
Incyte Corporation announced today results from the global, pivotal Phase III clinical program of ruxolitinib in patients with myelofibrosis (MF) at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting.
Study suggests COVID-19 vaccine confidence and hesitancy in the UK driven by trust, not misinformation
An interesting new study reports that vaccine hesitancy in the UK is driven not, as is commonly thought, by the so-called ‘infodemic' of misinformation that has characterized much public messaging during the COVID-19 pandemic. Instead, the personality of the individual, the ability to trust scientific and government leadership, political affiliations, and openness relative to the process of vaccine development was found to be key in the development of this attitude.
› Verified 8 days ago
Counselors
Dentists
Occupational Therapists
Pharmacists
Clinical Social Workers
Psychologists
Marriage Counselors